Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 18, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 19, 2025
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001493152-25-028597
Filed / recorded
Dec 19, 2025, 10:09 PM UTC
Added to OQRO
Oct 8, 2026, 2:51 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Lipocine Inc.
Issuer CIK
1535955
Ticker
LPCN
Reporting person
Mahesh V. Patel
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Dec 18, 2025
Transaction code
A
Shares / units
8,629
Price per share
$4.20
Acquired / disposed
Acquired (A)
Shares owned after
157,668
Ownership form
Direct
Amendment
No
Footnotes from the filing
Subject to vesting whereby 1/3 of the shares subject to the award will vest on December 18, 2026, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
